Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
  • Patent number: 11952426
    Abstract: Methods of treating cancers using a BCMAxCD3 bispecific antibody are described.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: April 9, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Homer Adams, Arnob Banerjee, Suzette Girgis, Jenna Goldberg, Tara Stephenson, Raluca Verona, Shun xin Wang lin
  • Patent number: 11939380
    Abstract: This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 26, 2024
    Assignee: LES LABORATOIRES SERVIER
    Inventors: Trine Lindsted, Michael Monrad Grandal, Eva Maria Carlsen Melander, Camilla Fröhlich, Mikkel Wandahl Pedersen, Michael Kragh, Johan Lantto, Monika Gad, Ivan David Horak
  • Patent number: 11932704
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: March 19, 2024
    Assignee: SANOFI
    Inventors: Zhi-Yong Yang, Gary J. Nabel, Lan Wu, Edward Seung, Ronnie Wei, Jochen Beninga, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange, Carsten Corvey
  • Patent number: 11891454
    Abstract: The present invention describes hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: February 6, 2024
    Assignee: Ichnos Sciences SA
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Patent number: 11879005
    Abstract: This invention relates to novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively.
    Type: Grant
    Filed: January 29, 2022
    Date of Patent: January 23, 2024
    Assignee: Numab Therapeutics AG
    Inventors: Sebastian Meyer, David Urech
  • Patent number: 11845805
    Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: December 19, 2023
    Assignee: GENMAB A/S
    Inventors: Brian Elliott, Tahamtan Ahmadi, Christopher W. L. Chiu, Esther C. W Breij, Ida Hiemstra, Maria N. Jure-Kunkel
  • Patent number: 11827717
    Abstract: The present invention provides anti-MASP-1 (mannan-binding lectin (MBL)-associated serine protease 1) antibodies and methods of using the same. In some embodiments, an anti-MASP-1 antibody of the invention binds to MASP-1 but does not bind to MASP-3. The invention also provides nucleic acids comprising a nucleotide sequence encoding an anti-MASP-1 antibody of the present invention. The invention further provides pharmaceutical compositions comprising an anti-MASP-1 antibody of the present invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 28, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshinao Ruike, Taku Fukuzawa
  • Patent number: 11802162
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: October 31, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
  • Patent number: 11780926
    Abstract: The present invention relates to a modular multivalent antigen-binding protein complex, use of the antigen-binding protein complex in medicine and use of the antigen-binding protein complex in the prophylaxis, treatment or diagnosis of a disorder or disease.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: October 10, 2023
    Assignee: UNIVERSITÄT STUTTGART
    Inventors: Oliver Seifert, Roland Kontermann, Fabian Richter
  • Patent number: 11725056
    Abstract: The invention relates to methods for treating or preventing progressive pulmonary fibrosis in a subject.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: August 15, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Paul W. Noble, Dianhua Jiang, Carol Jiurong Liang
  • Patent number: 11718667
    Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: August 8, 2023
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 11702469
    Abstract: The present disclosure relates to recombinant EGFL7, EGFL7 antibodies, and uses thereof.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: July 18, 2023
    Assignee: Ohio State Innovation Foundation
    Inventors: Adrienne M. Dorrance, Ramiro Garzon
  • Patent number: 11649284
    Abstract: Embodiments of the disclosure concern treatment of cancer utilizing methods and compositions that block CD47 such that tumor associated macrophages (TAMs) are not inhibited by CD47 and are able to phagocytose and kill tumor cells. In specific embodiments, the compositions and their use concern fusions of an entity that binds CD47 and an entity that binds cells having FC receptors, such as the FC receptor on TAMs. Certain embodiments concern gene therapy that produces a fusion of the ectodomain of SIRPa and the constant region of IgG4 at a localized tumor or tumor microenvironment, for example. In specific cases, gene transfer is utilized to deliver SIRPa fusion genes into a tumor and/or tumor microenvironment so that the molecules can be expressed locally to increase efficacy (given that the expression of the molecules will be highest at tumor sites) and decrease potential toxicities.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: May 16, 2023
    Assignee: Baylor College of Medicine
    Inventors: Stephen M. G. Gottschalk, Felicia Cao
  • Patent number: 11612149
    Abstract: The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3?, CD3?, and CD3? in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3?, CD3?, and CD3?. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: March 28, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Koichi Jishage, Otoya Ueda, Naoko Wada, Takahiro Ishiguro, Yasuko Kinoshita
  • Patent number: 11597766
    Abstract: The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19×CD3 bispecific single chain antibody construct to an adult patient in the need thereof.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 7, 2023
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Gerhard Zugmaier, Evelyn Degenhard
  • Patent number: 11572409
    Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 7, 2023
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE, CNRS
    Inventors: Daniel Olive, Christine Pasero
  • Patent number: 11572564
    Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: February 7, 2023
    Assignee: Genomatica, Inc.
    Inventor: Wei Niu
  • Patent number: 11505607
    Abstract: The present disclosure provides a bispecific single-chain antibody, recombinant oncolytic virus for expressing same and virus composition. The antibody named BiTEs-PD-L1 is a bispecific antibody capable of simultaneously binding CD3 and PD-L1 on the surfaces of tumor cells, and it can effectively activate T cells and guide T cells to kill tumor cells. The oncolytic virus oHSV2-BiTEs-PD-L1 is further developed by utilizing the BiTEs-PD-L1, it can reduce frequency and dosage of the administration. The present disclosure also confirmed several virus compositions with excellent antitumor effect.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: November 22, 2022
    Assignee: BINHUI BIOPHARMACEUTICAL CO., LTD.
    Inventors: Binlei Liu, Linkang Cai, Runyang Wang, Siqi Zhang, Han Hu
  • Patent number: 11505605
    Abstract: It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: November 22, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Osaka University
    Inventors: Tomoyuki Igawa, Takahiro Ishiguro, Shimon Sakaguchi, Hiroyoshi Nishikawa
  • Patent number: 11492399
    Abstract: Provided is an antibody that has a high binding activity to membrane-bound IgM on the surface of B cells and exhibits a growth inhibition effect on the B cells, even in the presence of soluble IgM in blood. A bispecific antibody, which binds to IgM and a B cell surface antigen.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: November 8, 2022
    Assignee: ZENYAKU KOGYO CO., LTD.
    Inventors: Yasukatsu Tsukada, Takahiro Ohashi, Hitoshi Miyashita, Satoko Tatebe, Jumpei Enami
  • Patent number: 11484543
    Abstract: The present invention relates to the discovery that mutant KCNJ5 is associated with adrenal diseases and disorders. The invention includes compositions and methods for the diagnosis and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: November 1, 2022
    Assignee: The Rockefeller University
    Inventors: Richard Lifton, Ute Scholl
  • Patent number: 11467169
    Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: October 11, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
  • Patent number: 11466094
    Abstract: The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: October 11, 2022
    Assignee: Genentech, Inc.
    Inventors: Yu-Waye Chu, Iraj Hosseini, Saroja Ramanujan, Kapil Gadkar, Chi-Chung Li
  • Patent number: 11440966
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: September 13, 2022
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Patent number: 11431687
    Abstract: A system and method for homomorphic encryption in a healthcare network environment is provided and includes receiving digital data over the healthcare network at a data custodian server in a plurality of formats from various data sources, encrypting the data according to a homomorphic encryption scheme, receiving a query at the data custodian server from a data consumer device concerning a portion of the encrypted data, initiating a secure homomorphic work session between the data custodian server and the data consumer device, generating a homomorphic work space associated with the homomorphic work session, compiling, by the data custodian server, a results set satisfying the query, loading the results set into the homomorphic work space, and building an application programming interface (API) compatible with the results set, the API facilitating encrypted analysis on the results set in the homomorphic work space.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: August 30, 2022
    Assignee: NANTHEALTH, INC.
    Inventors: Patrick Soon-Shiong, Harsh Kupwade-Patil, Ravi Seshadri, Nicholas J. Witchey
  • Patent number: 11414485
    Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: August 16, 2022
    Assignee: I-MAB BIOPHARMA (HANGZHOU) CO., LTD.
    Inventors: Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang, Wenqing Jiang, Yongqiang Wang
  • Patent number: 11406696
    Abstract: The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: August 9, 2022
    Inventors: Christiane Marie-Paule Simone Jeanne Feron, Stefan Jochen Kemmler, Michael Thomas Kowarik, Julien Laurent Quebatte
  • Patent number: 11401330
    Abstract: The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: August 2, 2022
    Assignee: Seagen Inc.
    Inventors: David A. Eavarone, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy
  • Patent number: 11396547
    Abstract: An anti-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: July 26, 2022
    Assignees: BEIJING DONGFANG BIOTECH CO., LTD., BEIJING JINGYITAIXIANG TECHNOLOGY DEVELOPMENT CO. LTD.
    Inventors: Yi Bai, Wen Zhang, Meng Xu, Shuang Pei, Yanlu Zan, Shengmei Wen
  • Patent number: 11371993
    Abstract: The present invention relates to the identification of biological markers of ovarian cancer. Specifically, cancer-associated autoantibodies to ANXA1, ARP3, SAHH, SERPH, ARAP1, OTUB1, ATP1A1, UBA1, and CFAH have been identified in subjects with early stage ovarian cancer. These autoantibodies can be utilised for a range of purposes including methods for detecting ovarian cancer, methods for screening for early stage ovarian cancer, and methods for assessing treatment response as well as disease progression and recurrence. The autoantibodies also represent prognostic markers of ovarian cancer development.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: June 28, 2022
    Assignee: ADELAIDE RESEARCH & INNOVATION PTY LTD
    Inventors: Peter Hoffmann, Martin Oehler, Karina Martin
  • Patent number: 11352438
    Abstract: An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and/or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and/or activated blood coagulation factor IX and (b) blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and/or treated more effectively.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 7, 2022
    Assignees: Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche AG
    Inventors: Koichiro Yoneyama, Christophe Schmitt
  • Patent number: 11345753
    Abstract: A TIM-3 antibody, an antigen-binding fragment thereof, and medical uses thereof are described. More specifically, the present invention provides a rat-derived antibody containing a CDR region of the TIM-3 antibody, a chimeric antibody or a human-derived antibody thereof, and a pharmaceutical composition containing the TIM-3 antibody and the antigen-binding fragment thereof, as well as uses thereof serving as a drug. In particular, the present invention provides uses of a human-derived TIM-3 antibody in the preparation of drugs for treating TIM-3-related conditions.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 31, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Zhuoxiao Cao, Yayuan Fu, Ting Zhang, Weikang Tao
  • Patent number: 11332541
    Abstract: The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: May 17, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Priyanka Gupta, Justin Scheer, Vladimir H. Voynov, Pankaj Gupta
  • Patent number: 11319364
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which a is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: May 3, 2022
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • Patent number: 11306156
    Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: April 19, 2022
    Assignee: ZYMEWORKS INC.
    Inventors: Mario Sanches, Thomas Spreter Von Kreudenstein, Dunja Urosev, Stacey A. L. Tom-Yew, Adam Louis Corper, Igor Edmondo Paolo D'Angelo, Yang-Chieh Chou, Surjit Bhimarao Dixit
  • Patent number: 11306142
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 19, 2022
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • Patent number: 11285207
    Abstract: The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 29, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Jens Fischer, Sabine Imhof-Jung, Christian Klein, Stefan Seeber, Patrick Alexander Aaron Weber
  • Patent number: 11279759
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 22, 2022
    Assignee: MedImmune, LLC
    Inventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
  • Patent number: 11225523
    Abstract: The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 18, 2022
    Assignee: Compugen Ltd.
    Inventors: Spencer Liang, Ling Leung, Sarah Whelan, Maya Kotturi, Eran Ophir, Arthur Machlenkin, Zoya Alteber, Meir Azulay, Sandeep Kumar, Radhika Desai, Christopher Chan, Kathryn Logronio
  • Patent number: 11219628
    Abstract: Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. For example, the compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunotherapy is bound and sequestered, without the use of cytotoxic preconditioning.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: January 11, 2022
    Assignee: AVM Biotechnology, LLC
    Inventor: Theresa Deisher
  • Patent number: 11214618
    Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 4, 2022
    Assignee: F-star Therapeutics Limited
    Inventors: Mihriban Tuna, Francisca Wollerton Van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
  • Patent number: 11198726
    Abstract: The invention relates to the combined use of certain bispecific, VEGF and Ang2 binding molecules with PD1 antagonists for the treatment of cancer. It further relates to pharmaceutical compositions and kits comprising such binding molecules and antagonists.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: December 14, 2021
    Assignee: Boerhinger Ingelheim International GmbH
    Inventors: Frank Hilberg, Marco Hans Hofmann, Markus Reschke, Flavio Solca
  • Patent number: 11192960
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: December 7, 2021
    Assignee: Sanofi
    Inventors: Zhi-Yong Yang, Gary J. Nabel, Lan Wu, Edward Seung, Ronnie Wei, Jochen Beninga, Ercole Rao, Wulf Dirk Leuschner, Christian Beil, Christian Lange, Carsten Corvey
  • Patent number: 11155627
    Abstract: An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 26, 2021
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Hyung-Chan Kim, Kyung Eun Kim, Yoon Sook Lee, Mi Young Cho
  • Patent number: 11141471
    Abstract: Disclosed are compositions of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In one embodiment the invention provides the use of NR2F6 silencing or gene editing in cord blood cells possessing anti-tumor activity in order to induce potentiated killer cells suitable for therapeutic use. In one embodiment said allogeneic cord blood killer cells are administered to initiate a cascade of antitumor immune responses, with initially responses mediated by allogeneic killer cells, and followed by endogenous immune responses.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: October 12, 2021
    Inventors: Thomas Ichim, David Koos, Harry Lander
  • Patent number: 11130808
    Abstract: Described herein are antibodies and mixtures of antibodies optionally produced by a host cell line, nucleic acids encoding the antibodies and mixtures of antibodies, host cells containing such nucleic acids, and methods of treatment using the antibodies, mixtures of antibodies, or nucleic acids encoding the antibodies or mixtures of antibodies. Also described are methods of producing mixtures of antibodies in host cells.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 28, 2021
    Assignee: QILU PUGET SOUND BIOTHERAPEUTICS CORPORATION
    Inventors: Wei Yan, Zhi Liu, Martin J. Pentony
  • Patent number: 11130810
    Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: September 28, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
  • Patent number: 11066483
    Abstract: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: July 20, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Junichi Nezu, Takahiro Ishiguro, Atsushi Narita, Akihisa Sakamoto, Yumiko Kawai, Tomoyuki Igawa, Taichi Kuramochi
  • Patent number: 11053305
    Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Q32 Bio Inc.
    Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
  • Patent number: RE49908
    Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: April 9, 2024
    Assignee: MedImmune, LLC
    Inventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst